SAN DIEGO, May 25 /PRNewswire-FirstCall/ -- Metabasis Therapeutics , announced today that Mr. John Beck, senior vice president of finance and CFO of Metabasis will present at the Friedman Billings Ramsey Growth Investor Conference at the Grand Hyatt Hotel in New York, NY. Mr. Beck is scheduled to present on Wednesday, May 31, 2006 at 10:30 a.m. Eastern Time, and is expected to provide an overview of the Company’s progress and discuss product candidates in clinical development.
To access the live broadcast and the subsequent archived recording of the presentation, please log onto the Company’s website at www.mbasis.com under the “Investors” section. The audio recording and presentation will be archived there for 30 days following the live presentation. Please connect to Metabasis’ website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.
About Metabasis (www.mbasis.com):
Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world’s most widespread and costly chronic diseases involving pathways in the liver. The Company has established a pipeline that includes clinical stage and preclinical product candidates targeting major diseases with significant unmet medical needs. Targeted diseases include major metabolic diseases such as diabetes, hyperlipidemia and obesity as well as liver diseases such as hepatitis and primary liver cancer. Metabasis has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic(TM) and HepDirect(R) technologies. Metabasis is continuing to identify and develop new product candidates using its proprietary technologies and expertise.
Metabasis Therapeutics
CONTACT: Constance Bienfait, Vice President, Investor Relations &Corporate Communications of Metabasis Therapeutics, Inc., +1-858-622-5575
Web site: http://www.mbasis.com//
